Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TACR3 | P29371 | 8/20 | 0.60 |
| ▸ | ACACA | Q13085 | 1/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12732312 | 0.91 | KDM4E (0.58) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL10610678 | 0.90 | KDM4E (0.71) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL10612092 | 0.87 | MAPT (0.71) | KDM4ESMN1; SMN2ALDH1A1ACACALMNA | |
| SCHEMBL5794038 | 0.86 | KDM4E (0.53) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12732313 | 0.86 | KDM4E (0.53) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL12732311 | 0.85 | KDM4E (0.53) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL28505794 | 0.85 | ACACA (0.78) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL14623967 | 0.85 | KDM4E (0.55) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8161422 | 0.84 | RAC1 (0.52) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL13350452 | 0.84 | KDM4E (0.74) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004026896-A2 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2004-04-01 | — | — | WO | claimed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2019-01-08 | — | — | US | disclosed |
| EP-2970195-B1 | PROCESSES FOR PRODUCING SOVAPREVIR | ACHILLION PHARMACEUTICALS INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-07-13 | — | — | US | disclosed |
| US-9481708-B2 | Process for producing Sovaprevir | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481708-B2 | Process for producing Sovaprevir | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| EP-3059241-A1 | INTERMEDIATES IN THE PREPARATION OF A BIS(BENZIMIDAZOLE)CYCLOPHANE DERIVATIVE | Achillion Pharmaceuticals, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| US-6329379-B1 | OLIGOPEPTIDES FOR INHIBITING HEPATITIS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6329417-B1 | RACEMATES, DIASTEREOISOMERS AND OPTICAL ISOMERS; PROTEASE INHIBITOR PEPTIDE ANALOG | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6323180-B1 | PROTEASE INHIBITORS; INHIBIT REPLICATION OF HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2001-11-27 | — | — | US | disclosed |
| CN-1323316-A | Hepatitis C tripeptide inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 2001-11-21 | — | — | CN | disclosed |
| CN-1315965-A | Hepatitis C inhibitor peptides | BOEHRINGER INGELHEIM CA LTD (CA) | 2001-10-03 | — | — | CN | disclosed |
| US-6268207-B1 | RESOLUTION OF ENANTIOMERS FROM A MIXTURE OF (1R,2S)/(1S,2S)-1-AMINO-2-VINYLCYCLOPROPYL CARBOXYLIC ACID METHYL ESTER COMPRISING THE STEP OF TREATING SAID MIXTURE WITH AN ESTERASE TO OBTAIN THE CORRESPONDING (1R,2S) ENANTIOMER | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-07-31 | — | — | US | disclosed |
| EP-1105422-A1 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-06-13 | — | — | EP | disclosed |
| EP-1105413-A2 | HEPATITIS C INHIBITOR TRI-PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009558-A1 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009543-A2 | HEPATITIS C INHIBITOR TRI-PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170196849-A1 | HCV NS-3 SERINE PROTEASE INHIBITORS | HPN, CPN1, PRSS1 | KDM4E 4633/4885SMN1; SMN2 3361/4885ALDH1A1 4292/4885 |
| US-10172846-B2 | HCV NS-3 serine protease inhibitors | HPN, CPN1, PRSS1 | KDM4E 4633/4885SMN1; SMN2 3361/4885ALDH1A1 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.